ArticlePloS one2016
Loss of Renal Tubular PGC-1α Exacerbates Diet-Induced Renal Steatosis and Age-Related Urinary Sodium Excretion in Mice.
Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 26 citations in OpenAlex.
- Lipids in kidney diseases: from systemic imbalance to intrarenal alterations of cellular lipid metabolism in rare and common kidney diseases.Journal of molecular medicine (Berlin, Germany) · 2026Review
- Liraglutide and renal mitochondrial homeostasis: targeting the "metabolism-inflammation-lithogenesis" axis in metabolic syndrome.Frontiers in pharmacology · 2026Review
- A Study on the Differences in Rumen Microbiota-Liver Gluconeogenesis-Mitochondrial Interaction Between Tibetan Sheep and Hu Sheep in the Qinghai-Tibet Plateau.Animals : an open access journal from MDPI · 2025Article
- Pharmacological potential of Chinese botanical drugs in managing chronic kidney disease by targeting mitochondrial quality control.Frontiers in pharmacology · 2025Review
- Therapeutic potential of artemisinin and its derivatives in managing kidney diseases.Frontiers in pharmacology · 2023Review
- Tubular β-catenin alleviates mitochondrial dysfunction and cell death in acute kidney injury.Cell death & disease · 2022Article
- Sulforaphane Protects against Unilateral Ureteral Obstruction-Induced Renal Damage in Rats by Alleviating Mitochondrial and Lipid Metabolism Impairment.Antioxidants (Basel, Switzerland) · 2022Article
- Glucose- and Non-Glucose-Induced Mitochondrial Dysfunction in Diabetic Kidney Disease.Biomolecules · 2022Review
- Article
- Renoprotective potentials of small molecule natural products targeting mitochondrial dysfunction.Frontiers in pharmacology · 2022Review
- Podocyte Injury in Diabetic Kidney Disease: A Focus on Mitochondrial Dysfunction.Frontiers in cell and developmental biology · 2022Review
- The Loss of Mitochondrial Quality Control in Diabetic Kidney Disease.Frontiers in cell and developmental biology · 2021Review
- Mitochondrial Dysfunction and Diabetic Nephropathy: Nontraditional Therapeutic Opportunities.Journal of diabetes research · 2021Review
- Ppargc1a Controls Ciliated Cell Development by Regulating Prostaglandin Biosynthesis.Cell reports · 2020Article
- Review
- Advances in understanding vertebrate nephrogenesis.Tissue barriers · 2020Article
- Late-onset renal hypertrophy and dysfunction in mice lacking CTRP1.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2020Article
- PGC-1α, a potential therapeutic target against kidney aging.Aging cell · 2019Review
- E6 Oncoproteins from High-Risk Human Papillomavirus Induce Mitochondrial Metabolism in a Head and Neck Squamous Cell Carcinoma Model.Biomolecules · 2019Article
- The Protective Effect of Alpha-Mangostin against Cisplatin-Induced Cell Death in LLC-PK1 Cells is Associated to Mitochondrial Function Preservation.Antioxidants (Basel, Switzerland) · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
The kidney has a high energy demand and is dependent on oxidative metabolism for ATP production. Accordingly, the kidney is rich in mitochondria, and mitochondrial dysfunction is a common denominator for several renal diseases. While the mitochondrial master regulator peroxisome proliferator-activated receptor γ coactivator 1α (PGC-1α) is highly expressed in kidney, its role in renal physiology is so far unclear. Here we show that PGC-1α is a transcriptional regulator of mitochondrial metabolic pathways in the kidney. Moreover, we demonstrate that mice with an inducible nephron-specific inactivation of PGC-1α in the kidney display elevated urinary sodium excretion, exacerbated renal steatosis during metabolic stress but normal blood pressure regulation. Overall, PGC-1α seems largely dispensable for basal renal physiology. However, the role of PGC-1α in renal mitochondrial biogenesis indicates that activation of PGC-1α in the context of renal disorders could be a valid therapeutic strategy to ameliorate renal mitochondrial dysfunction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.